Magnetic Resonance Imaging of the Prostate, Including Pre- and Postinterventions

Pritesh Patel; Aytekin Oto

doi:10.1055/s-0036-1586144

Seminars in Interventional Radiology, Table of Contents

Semin intervent Radiol 2016; 33(03): 186-195
DOI: 10.1055/s-0036-1586144

Review Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Magnetic Resonance Imaging of the Prostate, Including Pre- and Postinterventions

Authors

Pritesh Patel

¹Department of Radiology, University of Chicago, Chicago, Illinois
Aytekin Oto

¹Department of Radiology, University of Chicago, Chicago, Illinois

Abstract

This article systematically reviews the rationale for magnetic resonance imaging in prostate cancer, in detection and following various treatment methods. A basic discussion of the identification of prostate cancer is imperative to understand postintervention imaging. Each available therapy, including surgery, radiation, hormone therapy, and focal therapies will be discussed along with associated imaging findings, providing the reader with a better understanding of current interventions in prostate cancer and imaging.

Keywords

prostate cancer - prostate MRI - focal therapy - laser ablation - high-intensity focused ultrasound

Full Text

References

References
1 Moyer VA ; U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 157 (2) 120-134
2 Yacoub JH, Oto A, Miller FH. MR imaging of the prostate. Radiol Clin North Am 2014; 52 (4) 811-837
3 Kitzing YX, Prando A, Varol C, Karczmar GS, Maclean F, Oto A. Benign conditions that mimic prostate carcinoma: MR imaging features with histopathologic correlation. Radiographics 2016; 36 (1) 162-175
4 Oto A, Kayhan A, Jiang Y , et al. Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging. Radiology 2010; 257 (3) 715-723
5 Rosenkrantz AB, Taneja SS. Radiologist, be aware: ten pitfalls that confound the interpretation of multiparametric prostate MRI. AJR Am J Roentgenol 2014; 202 (1) 109-120
6 Litjens GJ, Elliott R, Shih NN , et al. Computer-extracted features can distinguish noncancerous confounding disease from prostatic adenocarcinoma at multiparametric MR imaging. Radiology 2016; 278 (1) 135-145
7 Vargas HA, Wassberg C, Akin O, Hricak H. MR imaging of treated prostate cancer. Radiology 2012; 262 (1) 26-42
8 Rischke HC, Schäfer AO, Nestle U , et al. Detection of local recurrent prostate cancer after radical prostatectomy in terms of salvage radiotherapy using dynamic contrast enhanced-MRI without endorectal coil. Radiat Oncol 2012; 7: 185
9 Boonsirikamchai P, Choi S, Frank SJ , et al. MR imaging of prostate cancer in radiation oncology: what radiologists need to know. Radiographics 2013; 33 (3) 741-761
10 Roach III M, Hanks G, Thames Jr H , et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006; 65 (4) 965-974
11 Ahmed A, Ali S, Sarkar FH. Advances in androgen receptor targeted therapy for prostate cancer. J Cell Physiol 2014; 229 (3) 271-276
12 Kim AY, Kim CK, Park SY, Park BK. Diffusion-weighted imaging to evaluate for changes from androgen deprivation therapy in prostate cancer. AJR Am J Roentgenol 2014; 203 (6) W645-50
13 Song I, Kim CK, Park BK, Park W. Assessment of response to radiotherapy for prostate cancer: value of diffusion-weighted MRI at 3 T. AJR Am J Roentgenol 2010; 194 (6) W477-82
14 Kim CK, Park BK, Lee HM, Kim SS, Kim E. MRI techniques for prediction of local tumor progression after high-intensity focused ultrasonic ablation of prostate cancer. AJR Am J Roentgenol 2008; 190 (5) 1180-1186
15 Kirkham AP, Emberton M, Hoh IM, Illing RO, Freeman AA, Allen C. MR imaging of prostate after treatment with high-intensity focused ultrasound. Radiology 2008; 246 (3) 833-844
16 Rouvière O, Lyonnet D, Raudrant A , et al. MRI appearance of prostate following transrectal HIFU ablation of localized cancer. Eur Urol 2001; 40 (3) 265-274
17 Haider MA, Davidson SR, Kale AV , et al. Prostate gland: MR imaging appearance after vascular targeted photodynamic therapy with palladium-bacteriopheophorbide. Radiology 2007; 244 (1) 196-204
18 Levy DA. Cryoablation. In: Polascik TJ, , ed. Imaging and Focal Therapy of Early Prostate Cancer. New York: Springer; 2013: 345-353
19 Rosenkrantz AB, Scionti SM, Mendrinos S, Taneja SS. Role of MRI in minimally invasive focal ablative therapy for prostate cancer. AJR Am J Roentgenol 2011; 197 (1) W90-96
20 Lindner U, Trachtenberg J. MRI-guided laser ablation for localized prostate cancer. In: Polascik TJ, , ed. Imaging and Focal Therapy of Early Prostate Cancer. New York: Springer; 2013: 297-307
21 van den Bos W, de Bruin DM, Muller BG , et al. The safety and efficacy of irreversible electroporation for the ablation of prostate cancer: a multicentre prospective human in vivo pilot study protocol. BMJ Open 2014; 4 (10) e006382
22 van den Bos W, de Bruin DM, van Randen A , et al. MRI and contrast-enhanced ultrasound imaging for evaluation of focal irreversible electroporation treatment: results from a phase I-II study in patients undergoing IRE followed by radical prostatectomy. Eur Radiol 2015;